179 results
Page 3 of 9
8-K
EX-10.1
y7ov3gw
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-10.2
4ily7 ktkqc7fdkgk0
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K/A
EX-10.5
4u147cuk ks5i4jop
1 Oct 20
Departure of Directors or Certain Officers
4:17pm
8-K
EX-10.2
3gbv3m319rymck xxm
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.3
6wph77dbydm
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.1
dum0k4gbreih 5p8czg
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.4
iqczqtw
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.5
thvijwh tu4f3b070ddr
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm
8-K
EX-10.1
uj1lav
19 Jun 20
Departure of Directors or Certain Officers
4:16pm
8-K
EX-10.1
ccx0a0m
27 Apr 20
Entry into a Material Definitive Agreement
4:18pm